Summary

  • Enterosgel found to both reduce time of treatment and lead to faster stool normalisation caused by diarrhoea from various digestive disorders.


Abstract

Background: 

In a prospective, controlled, randomized, open-label, single-center study, the efficacy and safety of polymethylsiloxane polyhydrate enterosorbent (Enterosgel) in the treatment of non-infectious diseases with diarrhoea has been proven

Methods: 

The patients were randomly divided into 3 groups: 62 patients (group 1) were indicated Enterosgel at a standard dose of 1 tablespoon 3 times a day between meals, 56 patients (group 2) were treated with dioctahedral smectite, 51 patients (group 3) were not prescribed enterosorbents. According to the cause of diarrhoea, the patients of group 1 were distributed as follows: 32 patients had antibiotic-associated diarrhoea, 8 patients – with irritable bowel syndrome and diarrhoea (IBS-D) and 8 patients – with ulcerative colitis, 6 patients with diverticular disease and 6 patients – with exocrine pancreatic insufficiency, 2 patients with NSAID-induced enteropathy.

The frequency of stool (the number of defecations during the day) and the duration of inpatient treatment (days) were evaluated. The results were then compared with those of patients from groups 2 and 3.

Results: 
The study has shown that the inclusion of Enterosgel into standard therapy of non-infectious diarrhoea, regardless of its cause, allows shortening the duration of treatment and contributes to faster stool normalization. The effectiveness of Enterosgel and dioctahedral smectite is comparable. The maximum effect was obtained when Enterosgel was used for the treatment of antibiotic-associated diarrhoea and IBS-D
Conclusions: 

The obtained results of using enterosorbent Enterosgel in the treatment of non-infectious diarrhea of various origins prove the effectiveness of including Enterosgel into standard therapy of these diseases

Source: https://rnlabs.com.au/wp-content/uploads/2022/06/Pavlov-Diarrhoea-2018-EN-II.-journal.pdf